重组人血管内皮抑制素治疗恶性胸腔积液的临床观察

目的观察重组人血管内皮抑制素(恩度)治疗恶性胸腔积液的近期疗效,评价恩度局部应用的疗效、安全性及耐受性。方法将病例随机分为两组:A组(治疗组)18例,B组(对照组)14例。治疗组胸腔注入恩度30 mg+0.9%氯化钠注射液40 m l;对照组胸腔注入顺铂40 mg+0.9%氯化钠注射液60 m l,每周2次,共2~4次。结果 A组(治疗组)中CR 5例,PR 9例,ND 4例,有效率77.8%。B组(对照组)CR2例,PR5例,ND7例,有效率50%。A组副反应较轻。结论顺铂和恩度胸腔灌注治疗恶性胸腔积液,均能有效控制恶性胸腔积液,但恩度有效率高于顺铂组,而且副反应较轻。

Clinical observation of Endostar in the treatment of malignant pleural effusion

Objective To observe the clinical efficacy of recombinant human endostatin(Endostar)for control malignant pleural effusion,evaluate the safety and tolerability of intracavitary infusion of Endostar.Methods Thirty-two malignant tumors patients were divided into two groups.A group(therapy group,18 cases)were treated with Endostar into thoracic cavity.B group(control group,14 cases)were treated with Cisplatin,twice a week,in 2~3 rounds.Results The efficacy of therpy group:5 cases of CR,9 cases of PR,4 cases of...